IBDEI0N3 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10546,1,4,0)
 ;;=4^B37.41
 ;;^UTILITY(U,$J,358.3,10546,2)
 ;;=^5000616
 ;;^UTILITY(U,$J,358.3,10547,0)
 ;;=B37.42^^68^671^10
 ;;^UTILITY(U,$J,358.3,10547,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10547,1,3,0)
 ;;=3^Candidal Balanitis
 ;;^UTILITY(U,$J,358.3,10547,1,4,0)
 ;;=4^B37.42
 ;;^UTILITY(U,$J,358.3,10547,2)
 ;;=^5000617
 ;;^UTILITY(U,$J,358.3,10548,0)
 ;;=A59.03^^68^671^96
 ;;^UTILITY(U,$J,358.3,10548,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10548,1,3,0)
 ;;=3^Trichomonal Cystitis & Urethritis
 ;;^UTILITY(U,$J,358.3,10548,1,4,0)
 ;;=4^A59.03
 ;;^UTILITY(U,$J,358.3,10548,2)
 ;;=^5000349
 ;;^UTILITY(U,$J,358.3,10549,0)
 ;;=E87.6^^68^671^57
 ;;^UTILITY(U,$J,358.3,10549,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10549,1,3,0)
 ;;=3^Hypokalemia
 ;;^UTILITY(U,$J,358.3,10549,1,4,0)
 ;;=4^E87.6
 ;;^UTILITY(U,$J,358.3,10549,2)
 ;;=^60610
 ;;^UTILITY(U,$J,358.3,10550,0)
 ;;=F52.0^^68^671^56
 ;;^UTILITY(U,$J,358.3,10550,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10550,1,3,0)
 ;;=3^Hypoactive Sexual Desire Disorder
 ;;^UTILITY(U,$J,358.3,10550,1,4,0)
 ;;=4^F52.0
 ;;^UTILITY(U,$J,358.3,10550,2)
 ;;=^5003618
 ;;^UTILITY(U,$J,358.3,10551,0)
 ;;=F52.22^^68^671^93
 ;;^UTILITY(U,$J,358.3,10551,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10551,1,3,0)
 ;;=3^Sexual Arousal Disorder,Female
 ;;^UTILITY(U,$J,358.3,10551,1,4,0)
 ;;=4^F52.22
 ;;^UTILITY(U,$J,358.3,10551,2)
 ;;=^5003621
 ;;^UTILITY(U,$J,358.3,10552,0)
 ;;=F52.8^^68^671^94
 ;;^UTILITY(U,$J,358.3,10552,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10552,1,3,0)
 ;;=3^Sexual Dysfnct Not d/t Substance/Known Physiological Cond
 ;;^UTILITY(U,$J,358.3,10552,1,4,0)
 ;;=4^F52.8
 ;;^UTILITY(U,$J,358.3,10552,2)
 ;;=^5003624
 ;;^UTILITY(U,$J,358.3,10553,0)
 ;;=F52.21^^68^671^33
 ;;^UTILITY(U,$J,358.3,10553,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10553,1,3,0)
 ;;=3^Erectile Disorder,Male (Psychogenic)
 ;;^UTILITY(U,$J,358.3,10553,1,4,0)
 ;;=4^F52.21
 ;;^UTILITY(U,$J,358.3,10553,2)
 ;;=^5003620
 ;;^UTILITY(U,$J,358.3,10554,0)
 ;;=I12.9^^68^671^55
 ;;^UTILITY(U,$J,358.3,10554,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10554,1,3,0)
 ;;=3^Hypertensive Kidney Disease Chronic w/ Stg 1-4
 ;;^UTILITY(U,$J,358.3,10554,1,4,0)
 ;;=4^I12.9
 ;;^UTILITY(U,$J,358.3,10554,2)
 ;;=^5007066
 ;;^UTILITY(U,$J,358.3,10555,0)
 ;;=N04.9^^68^671^69
 ;;^UTILITY(U,$J,358.3,10555,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10555,1,3,0)
 ;;=3^Nephrotic Syndrome w/ Unspec Morphologic Changes
 ;;^UTILITY(U,$J,358.3,10555,1,4,0)
 ;;=4^N04.9
 ;;^UTILITY(U,$J,358.3,10555,2)
 ;;=^5015540
 ;;^UTILITY(U,$J,358.3,10556,0)
 ;;=N02.9^^68^671^50
 ;;^UTILITY(U,$J,358.3,10556,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10556,1,3,0)
 ;;=3^Hematuria w/ Unspec Morphologic Changes,Recurrent & Persistent
 ;;^UTILITY(U,$J,358.3,10556,1,4,0)
 ;;=4^N02.9
 ;;^UTILITY(U,$J,358.3,10556,2)
 ;;=^5015520
 ;;^UTILITY(U,$J,358.3,10557,0)
 ;;=N06.9^^68^671^86
 ;;^UTILITY(U,$J,358.3,10557,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10557,1,3,0)
 ;;=3^Proteinuria Isolated w/ Unspec Morphologic Lesion
 ;;^UTILITY(U,$J,358.3,10557,1,4,0)
 ;;=4^N06.9
 ;;^UTILITY(U,$J,358.3,10557,2)
 ;;=^5015558
 ;;^UTILITY(U,$J,358.3,10558,0)
 ;;=N05.9^^68^671^66
 ;;^UTILITY(U,$J,358.3,10558,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10558,1,3,0)
 ;;=3^Nephritic Syndrome w/ Unspec Morphologic Changes
 ;;^UTILITY(U,$J,358.3,10558,1,4,0)
 ;;=4^N05.9
 ;;^UTILITY(U,$J,358.3,10558,2)
 ;;=^5134086
 ;;^UTILITY(U,$J,358.3,10559,0)
 ;;=N07.9^^68^671^68
 ;;^UTILITY(U,$J,358.3,10559,1,0)
 ;;=^358.31IA^4^2
